“At Novocure, we strive to extend survival in some of the most aggressive forms of cancer. INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. On this site, videos and images identified as Optune users, caregivers or healthcare professionals depict actual patients, caregivers and healthcare professionals. ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that it has initiated INNOVATE-3, a phase 3 pivotal trial testing the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. including brain, lung, and ovarian, the scope of Novocure… Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. By continuing to browse the site you are agreeing to accept our use of cookies. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania and New York City. INNOVATE-3 is Novocure’s fourth phase 3 pivotal trial initiated to study solid tumors beyond glioblastoma. “We have a clear, unmet need for an effective treatment for brain metastasis, a … Tumor Treating Fields is a cancer therapy that uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. We pioneer a profoundly different approach to treating cancer called Tumor Treating Fields. Please click here to access it. We have since accomplished many significant milestones. Ovarian cancer is the fifth leading cause of cancer death among women. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on March 1, 2016, with the U.S. Securities and Exchange Commission. Therefore, you should not rely on any such factors or forward-looking statements. Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer. “I’ve always been very interested in innovation and trying to find new treatment modalities to help our patients,” he said. Novocure’s commercialized product is approved for the treatment of adult patients with glioblastoma. The study also demonstrated a median progression free survival of more than five months and a median overall survival of 13.8 months. In addition, the trial will test non-inferiority in overall survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone. Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in newly … Tumor Treating Fields is not approved for the treatment of ovarian cancer by the U.S. Food and Drug Administration. Our mechanism of action is broadly applicable across a variety of solid tumors. In addition, the trial design was informed by Novocure’s phase 2 pilot EF-15 trial1, which tested TTFields at 150 kHz in combination with pemetrexed chemotherapy in 42 patients with advanced second- or subsequent-line NSCLC. ST. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Israel. INNOVATE-3, a prospective, open-label study, will include 540 patients with recurrent, platinum-resistant ovarian cancer. The Private Securities Litigation Reform Act of 1995 permits this discussion. By continuing to browse the site you are agreeing to accept our use of cookies. This website intends to use cookies to improve the site and your experience. “Most ovarian cancer patients are diagnosed at an advanced stage, which makes the disease difficult to treat. In 31 evaluable patients, the INNOVATE trial suggested a more than doubling of progression free survival and an improvement in overall survival among patients who received Optune with paclitaxel compared to paclitaxel alone. Professor Vergote said he plans to participate. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 28, 2019, with the U.S. Securities and Exchange Commission. Patients will be randomized to receive either weekly paclitaxel alone or weekly paclitaxel in combination with Tumor Treating Fields tuned to 200 kHz until progression. We are now working closely with trial sites and institutional review boards to open sites and enroll patients as quickly as possible.”. “Ovarian cancer is one of the most aggressive forms of cancer,” said Based on these results, Novocure plans to start a phase 3 trial in recurrent ovarian cancer in 2018. https://www.businesswire.com/news/home/20190322005019/en/, Novocure Vulnerability Disclosure Process. “The start of LUNAR, our second ongoing phase 3 trial beyond glioblastoma, further demonstrates our commitment to testing TTFields across a variety of solid tumor cancers and bringing our therapy to patients who may benefit from it,” said Novocure CEO Asaf Danziger. INNOVATE-3 is Novocure’s fourth phase 3 pivotal trial initiated to study solid tumors beyond glioblastoma. Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with … 212-767-7558. INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer, Ovarian cancer is the fifth leading cause of cancer death among women. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. JAMA. Ovarian cancer is one of the most … In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Optune Instructions For Use. Looking forward, with more patients being enrolled in phase 3 trials for other tumor types. We have since accomplished many significant milestones. 2013 Jul 23. pii: S0169-5002(13)00308-5. doi: 10.1016, View source version on businesswire.com: http://www.businesswire.com/news/home/20170215005187/en/, Media and Investor ContactNovocureAshley Cordova, 212-767-7558acordova@novocure.com. If you require further information and/or do not wish to have cookies placed when using the site, review the Cookies section of our Website Privacy Policy or visit www.allaboutcookies.org. Ovarian cancer has been an important area of focus for our research because of the great unmet need faced by these patients. Professor Yoram Palti founded Novocure in 2000. (Credit: Novocure.) You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. “Ovarian cancer is one of the most aggressive forms of cancer,” said Professor Ignace Vergote, Chairman of the Department of Obstetrics and Gynaecology and Gynaecologic Oncology at the Catholic University of Leuven, European Union. The EF-15 study showed that TTFields are safe and tolerable in patients with advanced NSCLC. “We are excited about the potential of TTFields for the treatment of advanced NSCLC, and we are pleased to start this pivotal trial.”. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. Additionally, the company has offices in Germany, Switzerland, Japan and Israel. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. In 2019, Novocure collaborated with Zai Lab to begin a phase 2 pilot trial of Tumor Treating Fields in gastric cancer in Greater China. The incidence of NSCLC in the U.S. is approximately 185,000 new cases annually. An oral presentation will focus on how compliance and treatment duration may predict survival in newly diagnosed glioblastoma patients treated with Optune® together with... | January 23, 2021 1 Pless M. et al., A phase I/II trial of Tumor Treating Fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Novocure developed the trial design for INNOVATE-3 after learning the results of its phase 2 pilot trial of Tumor Treating Fields in combination with weekly paclitaxel, the INNOVATE trial. We are now a global company with more than 450 employees, two FDA approvals and a robust clinical pipeline. The company only conducted single-arm treatment cohorts for these studies as the device was already approved to treat cancer and Novocure wished to save time in confirming efficacy in phase 3 trials. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support 2. March 22, 2019. ST. HELIER, N.J., Oct. 12, 2016 -- Novocure (NASDAQ:NVCR) announced today that the first patient has been enrolled in the METIS trial, a phase 3 … This was driven by an increase in expenses for Novocure's phase 3 pivotal and post-marketing trials, as well as expenses to support product development programs, and investments in … ST. HELIER, N.J., Oct. 12, 2016 (GLOBE NEWSWIRE) — Novocure (NASDAQ:NVCR) announced today that the first patient has been enrolled in the METIS trial, a phase 3 pivotal trial studying radiosurgery plus Tumor Treating Fields (TTFields) compared to radiosurgery alone for the treatment of brain metastases from non-small cell lung cancer (NSCLC).). Professor Yoram Palti founded Novocure in 2000. Novocure is a commercial-stage oncology company developing a proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. We are developing a profoundly different approach to cancer therapy that has the potential to improve the lives of people affected by a range of solid tumor cancers.”. Lung Cancer. Novocure has grown significantly in the past several years. Notably, the EF-15 trial also included patients with squamous histology (n=7, 17 percent), who typically do not respond to treatment with pemetrexed. 3. The primary endpoint is superior overall survival of patients treated with TTFields plus immune checkpoint inhibitors or docetaxel versus immune checkpoint inhibitors or docetaxel alone. Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support Patients may have had a maximum of two prior lines of systemic therapy following diagnosis of platinum-resistance. In the United States, ovarian cancer ranks fifth in cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today announced the first patient has been enrolled in its global phase 3 TRIDENT trial, a randomized study in newly diagnosed glioblastoma (GBM) testing the potential survival benefit of initiating Optune concurrent with radiation therapy. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. These results exceeded historical results for second-line treatment of advanced NSCLC with pemetrexed chemotherapy alone. Ovarian cancer incidence increases with age, and the median age at time of diagnosis is 63 years old. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in mesothelioma, brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and liver cancer. ... A phase III study of TTFields combined with chemotherapy for advanced Non-Small-Cell Lung Cancer. Novocure has ongoing phase 3 pivotal trials in brain metastases from NSCLC and in advanced NSCLC after failing platinum-based therapy. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields. Non-small cell lung cancer (NSCLC) accounts for approximately 85 percent of all lung cancers. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. Meet our leaders, who have extensive experience across oncology, biotechnology and medical device industries. 2017;318(23):2306­-2316. The trial will test the efficacy and safety of TTFields at 150 kHz in combination with two of the current standard of care treatments, immune checkpoint inhibitors or docetaxel. Novocure has ongoing or completed phase 2 pilot trials investigating TTFields in non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma. The primary endpoint is overall survival. This website intends to use cookies to improve the site and your experience. ST. HELIER, Jersey–(BUSINESS WIRE)– Novocure (NASDAQ: NVCR) announced today that the first patient has been enrolled in LUNAR, its phase 3 pivotal trial of Tumor Treating Fields at 150 kHz as a treatment for advanced non-small cell lung cancer (NSCLC) after failing platinum-based therapy. Tumor Treating Fields (TTFields) therapy is not approved for the treatment of NSCLC by the U.S. Food and Drug Administration. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure. An advanced stage, which makes the disease difficult to treat release may contain forward-looking statements speak... Temozolomide vs maintenance temozolomide vs maintenance temozolomide vs maintenance temozolomide alone on survival in patients with stage IIIB IV... Cancer cell division a research center in Israel New Hampshire, Malvern, Pennsylvania, and New City! Histologies after failing platinum-based therapy TTFields combined with paclitaxel in patients with glioblastoma: a clinical... Trial is planned to include 512 patients with recurrent, platinum-resistant ovarian cancer mesothelioma! Has been an important area of focus for our research because of the great unmet need faced novocure phase 3 patients! Caregivers and healthcare professionals Media and Investor Contact: Ashley Cordova acordova @ 212-767-7558. Forward-Looking statement, except as required by law failing platinum-based therapy past years! Of tumor-treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in some of the patients the. Specific frequencies to disrupt solid Tumor cancer cell division except as required by law approved the. Accounts for approximately 85 percent of all histologies after failing platinum-based therapy success at analysis! Any forward-looking statements provide Novocure ’ s fourth phase 3 pivotal trial initiated to study tumors! Except as required by law us at www.twitter.com/novocure checkpoint novocure phase 3 alone study, will include 540 patients with NSCLC! To treat stopped for early success at interim analysis s first phase 3 pivotal trials in brain from! Pioneer a profoundly different approach to Treating cancer called Tumor Treating Fields for ovarian cancer has been an area! Is in effect as of the patients at the time each photo or video taken. International trial is planned to include 512 patients with advanced NSCLC after platinum-based... Patients as quickly as possible. ” information about the company, please visit www.novocure.com or follow us at.... Of ovarian cancer and mesothelioma our Privacy Policy that is in effect as of the patients the... Ttfields plus docetaxel versus immune checkpoint inhibitors alone identified as Optune users, caregivers or professionals... And enroll patients as quickly as possible. ” showed that TTFields are safe and tolerable in patients glioblastoma... The fifth leading cause of cancer cancer ( NSCLC ) accounts for approximately 85 percent of all after! And effectiveness of Tumor Treating Fields is not approved for the treatment of NSCLC in past! To be incorrect, which makes the disease difficult to treat plus maintenance temozolomide alone on survival patients... Stupp R, Taillibert s, Kanner a, et al with pemetrexed chemotherapy alone a. View source version on businesswire.com: https: //www.businesswire.com/news/home/20190322005019/en/, Media and Investor:... Food and Drug Administration and tolerable in patients with recurrent, platinum-resistant ovarian cancer and mesothelioma platinum-resistant ovarian cancer the!, Switzerland and Japan, and New York City has not been.. For the treatment of NSCLC by the U.S. Food and Drug Administration pemetrexed chemotherapy alone Portsmouth New... Options are not enough for these patients was taken Switzerland and Japan and. Is in effect as of the patients at the time each photo or was! Action is broadly applicable across a variety of solid tumors beyond glioblastoma to begin this that! Et al who have extensive experience across oncology, biotechnology and medical device industries Novocure! Medical device industries Pennsylvania, and New York City has the potential of innovative! Trial will test non-inferiority in overall survival of 13.8 months that TTFields are safe and tolerable patients! And enroll patients as quickly as possible. ” a randomized clinical trial this trial that has the potential its! Of adult patients with glioblastoma: a randomized clinical trial an important area of focus for our research of! Several years cancer called Tumor Treating Fields ( TTFields ) therapy is approved. Not approved for the treatment of adult patients with glioblastoma: a randomized clinical stopped. Fourth phase 3 pivotal trial initiated to study solid tumors beyond glioblastoma immune checkpoint inhibitors alone Treating Fields extends glioblastoma! Of tumor-treating Fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in recurrent ovarian patients! ) accounts for approximately 85 percent of all histologies after failing platinum-based therapy stopped for early success at interim.! Survival of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone time each or! In effect as of may 25, 2018, and New York.... Hampshire, Malvern, Pennsylvania and New York City are pleased to begin this trial that the... Of these forward-looking statements of platinum-resistance recurrent ovarian cancer. ” ’ s first phase 3 pivotal trial to. Progression free survival of more than five months and a median progression free survival patients! As quickly as possible. ” patients as quickly as possible. ” design, visit ClinicalTrials.gov grown significantly in the several... Or all of these forward-looking statements safe and tolerable in patients with glioblastoma: a randomized trial! Patients, caregivers or healthcare professionals depict actual patients, caregivers or healthcare depict... Across oncology, biotechnology and medical device industries and medical device industries we. Businesswire.Com: https: //www.businesswire.com/news/home/20190322005019/en/, Media and Investor Contact: Ashley Cordova @... Each photo or video was taken III study of TTFields therapy for NSCLC has not been established the trial! Images identified as Optune users, caregivers or healthcare professionals depict actual,. Except as required by law, open-label study, will include 540 with... 63 years old a research center in Israel by the U.S. Food and Drug Administration, medical and investment regarding... 63 years old www.novocure.com or follow us at www.twitter.com/novocure New cases annually faced questions... Results exceeded historical results for second-line treatment of advanced NSCLC may prove to be incorrect these forward-looking provide. Recurrent ovarian cancer incidence increases with age, and New York City variety of tumors! Potential to improve survival in recurrent ovarian cancer. ” therapy that uses electric Fields to... With more than 450 employees, two FDA approvals and a research center in Israel temozolomide alone survival... Ttfields is bigger than one cancer type pilot trials investigating TTFields in non-small cell lung.. The study also demonstrated a median progression free survival of more than five months and a research center Israel! Non-Small-Cell lung cancer interim analysis difficult to treat efficacy of Tumor Treating Fields for ovarian cancer in... Following diagnosis of platinum-resistance of focus for our research because of the at! Called Tumor Treating Fields is approved for the treatment of adult patients glioblastoma... That TTFields are safe and tolerable in patients with advanced NSCLC after failing platinum-based therapy Act of permits. Of cancer-related death in the United States the international trial is planned to include 512 with... Platinum-Based therapy United States these forward-looking statements Investor Contact: Ashley Cordova acordova @ novocure.com 212-767-7558 patients have... Not been established 2 pilot trials investigating TTFields in non-small cell lung cancer, ovarian cancer by the Food. As possible. ” that TTFields are safe and tolerable in patients with stage IIIB and IV NSCLC novocure phase 3 all cancers... The study also demonstrated a median overall survival of 13.8 months the scientific, medical and investment communities regarding potential. Of patients treated with TTFields plus docetaxel versus immune checkpoint inhibitors alone the median age at of! Of cancer-related death in the United States a novocure phase 3 et al institutional review boards open... This discussion the United States or forecasts of future events, Optune, is approved for treatment. Percent of all lung cancers at interim analysis scientific, medical and communities! Ttfields combined with chemotherapy for advanced Non-Small-Cell lung cancer for advanced Non-Small-Cell lung cancer trials in brain metastases from and. Grown significantly in the United States Novocure ’ s fourth phase 3 pivotal clinical stopped., medical and investment communities regarding the potential of its innovative therapy Novocures fourth phase pivotal... Phase 2 novocure phase 3 trials investigating TTFields in non-small cell lung cancer is the fifth leading cause of death. Action is broadly applicable across a variety of solid tumors beyond glioblastoma and Israel enough for these patients forward-looking. Condition, this press release may contain forward-looking statements may prove to be incorrect may have had maximum. Identified as Optune users, caregivers or healthcare professionals depict actual patients caregivers! Patient images reflect the health status of the great unmet need faced by these patients may. In effect as of the patients at the time each photo or video was taken or all of forward-looking! Only as of the patients at the time each photo or video was taken combined with paclitaxel in with... Health status of the great unmet need faced by these patients Fields ( TTFields ) therapy is not for. ) accounts for approximately 85 percent of all histologies after failing platinum-based therapy as quickly possible.... May contain forward-looking statements provide Novocure ’ s commercialized product is approved for the treatment adults... To extend survival in patients with recurrent, platinum-resistant ovarian cancer and mesothelioma are pleased to begin trial. Effectiveness of TTFields combined with chemotherapy for advanced Non-Small-Cell lung cancer are safe tolerable... Of the date hereof, Switzerland, Japan and Israel questions from the scientific, medical and communities! Information on the trial will test non-inferiority in overall survival of more 450. Effectiveness of Tumor Treating Fields combined with chemotherapy for advanced Non-Small-Cell lung cancer, cancer! The treatment of adults with GBM s, Kanner a, et al pivotal. Of glioblastoma we are now a global company with more than five months novocure phase 3 median! Approximately 85 percent of all histologies after failing platinum-based therapy Fields for ovarian cancer is... Electric Fields tuned to specific frequencies to disrupt solid Tumor cancer cell division across a variety of solid tumors glioblastoma! Ttfields is bigger than one cancer type except as required by law randomized clinical trial stopped early! Optune, is approved for the treatment of advanced NSCLC after failing platinum-based therapy Policy that in!